

Michigan Medicine

HEMATOPATHOLOGY CONSULT REQUISITION

MICUICAN MEDICINE	Laboratories (MLabs)	Client	Patient Peg or M	1DNI-		
MICHIGAN MEDICINE UNIVERSITY OF MICHIGAN	N-LNC Specimen Processing	Client	Patient Reg or M	ikiv:		
LABORATORIES	2800 Plymouth Rd, Bldg 35 Ann Arbor, MI 48109-2800		Patient Name:	Last	First	MI
734.936.2598 • 800.862.7284 • mlabs.umich.edu		Ward	Birthdate:		Gender: OM O	
AX. 734.730.0733			Ordering Doctor	::Last	First	NPI#
Patient Address	City	Sta	te ZIP	Home Ph	one #	
Policy Holders Name Primary In:		urance (Card Name) Prima		ary Policy/Contract #	Primary Group #	Policy Holders DOB
Policy Holders Name	Secondary	Insurance (Card N	lame) Seco	ndary Policy/Contrac	ct # Secondary Group	# Policy Holders DOB
Bill To: Client/Red				facility will be billed.	e information is not included o For Medicare patients classifie	ed as a hospital inpatient or
☐ Medicare =	= □ In Patient on DOS □ Out Pa	tient on DOS ⊔N	ICD-1	0 Codes are required for	ate of service, charges must be billing. When ordering tests for whally necessary for the diagnosis an	nich reimbursement will be sought,
REFERRING PHYSIC Referring Physician	CIAN TO BE CONTACTED W Referrir	TITH RESULTS AI	ND/OR QUESTIC	ONS	Phone	Fax
Address		City	/	State	ZIP	Country
This request to order tests test ordered and (2) the o	s from MLabs certifies to MLabs that (1) rdering physician has authorization fror	the ordering physician n the patient permittin	n has obtained written g MLabs to report resu	informed consent from t llts for each test ordered	he patient as required by applicab to the ordering physician.	le state or federal laws for each
STAT PROCESS						
Collection Date:	Time:		_ (Oam Opm) Fo	otnote: Case/Accn	#	
□ Bone Marrow Aspirate □ Peripheral Blood □ Fresh Tissue □ Fluie	☐ Bone Marrow Core ☐ BM Core ☐ Na Heparin(G) green # ☐ Na Heparin(G) green # d ☐ Other source	□ EDTA(L) lave	ender # BN ender # PB Paraffin Block #	Unstained Slides (no H&E Slides #	t baked) #	
	Y/DIAGNOSIS (REQUIRED)		US: NEW DIAGN			RESIDUAL DISEASE
□ Non-Hodgkin Lympho □ Follicular Lymphom □ MALT Lymphoma □ CLL/SLL □ Plasma Cell Dyscrasia □ Hodgkin Lymphoma	☐ Burkitt vs Large B-Cell☐ Hairy Cell Leukemia (HCL)	☐ Acute Leukem ☐ AML ☐ B-A ☐ APL ☐ Myeloprolifera Disorders (MP ☐ CML ☐ PV ☐ PMF	LL	/topenias	TREATMENT ☐ None ☐ Current ☐ >1 Month ago ☐ Induction days ago ☐ Radiotherapy	CHEMOTHERAPY Anti-CD19 Anti-CD20 Anti-CD38 GCSF GMCSF EPO TKI Other:
The tests below may in	nclude microdissection and/or refl	ex testing at a sepai	rate additional charg	ge. All tests include pa	athologist interpretation at a	separate additional charge.
SPECIMENS: Bone mai morphology evaluation for Flow Cytometry an if indicated. REQUIRED: BM clot, B 3 BM core touch prep BM min. 2 mL, 1 laven most recent CBC and PB 3 mL. AUTHORIZATION: In a	MARY DIAGNOSIS ON REFERRED rrow study includes: bone marrow n, Cytogenetics evaluation, and triage d/or Molecular Diagnostics studies M core biopsy, 5 BM aspirate smears, slides, 2 PB smears, 3 green top (G) der top (L) BM min. 2 mL, copy of platelet count or 1 lavender top (L) ddition to what has been ordered, is authorized to add other testing as aluation. (Culture and Karyotype) GArray G, TR BES MYC [t(8q24)] GH/CCND1 [t(11;14)] GH/CCND1 [in(14)] TRAD [inv(14)] GRIF2 (Xp22.33/Yp11.32) MDS Panel (reflex)	CSF specimens please Leukemia / Lympl Select either LEUK (LEUKS) Non-bl (LEUKB) Periph Panel to be d Stem cell neo Mature lymph LGI/NK ms Cutaneous Total T-cell epitope Plasma cell/N HOLD until not (Please contal after submiss for flow cyto (MRDMM) Minir (MAST) Mastoco (RITUX) Rituxim (PNH) Paroxysm Hemoglobinuria	cent WBC, platelet and dife include copy of fluid countoma workup So or LEUKB and 1 or nood specimen etermined by testing laplasm/Acute leukemia hoid leukemia/Non-Horackers HCL marker cell Lymphoma (T-cell sissonly) lultiple myeloma otified by client inct MLabs (800-862-728 sion to ensure optimal metry analysis) mal Residual Disease for ytosis ab nal Nocturnal (PNH)	nt and differential. nore of the suboptions F, TR, G G aboratory dgkin lymphoma s ubsets and pan 84) by 12 noon day specimen viability Multiple Myeloma Y G (BM only) G (PB only) ACD -soln A or soln B (PB only)	□ KIT Mutation for AML - Exon □ PML/RARA t(15;17) Transloca: □ TP53 Mutation in Malignancy MYELOPROLIFERATIVE NE □ Myeloid NGS Panel □ JAK2 V617F Mutation □ JAK2 V617F is negative, perform □ JAK2 Exon 12 Mutation □ CALR Mutation □ MPL Mutation □ KIT D816V Mutation □ BCR/ABL1 Analysis, Quantita □ BCR/ABL1 Kinase Domain M □ TP53 Mutation in Malignancy □ LYMPHOMA □ TP53 Mutation in Malignancy □ B Cell Clonality (IGH Gene Rea □ B Cell Clonality (IGK Gene Rea □ T Cell Clonality (TRG Gene Rea □ T Cell Clonality (TRB Gene	ation (PCR) Quantitative T, L T, L T, L OPLASMS (MPN) / CML L D: CALR MPL JAK2 Exon 12 L L L L L L L L L T, L L L L T, L L L L L L L L L L L L L L L L L L L
	iire an additional green top:	☐ CEBPA Mutation☐ IDH1 and IDH2	CEBPA Mutation			S, T, L